366
Participants
Start Date
April 7, 2022
Primary Completion Date
November 30, 2025
Study Completion Date
September 30, 2026
BLU-222
Oral administration
Carboplatin
IV Infusion
Ribociclib
Oral administration
Fulvestrant
Intra muscular administration
Columbia University Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, New York
Hospital of the Fox Chase Cancer Center, Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Instituto Europeo di Oncologia, Milan
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore
University of Virginia Comprehensive Cancer Center, Charlottesville
UNC Hospitals at Chapel Hill - The University of North Carolina at Chapel Hill, Chapel Hill
Florida Cancer Specialists, Sarasota
Vanderbilt Breast Center at One Hundred Oaks, Nashville
Henry Ford Health System, Detroit
University of Chicago Medical Center, Chicago
University of Arkansas for Medical Sciences, Little Rock
OU Health Stephenson Cancer Center, Oklahoma City
MD Anderson Cancer Center, Houston
University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Stanford Women's Cancer Center, Stanford
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Fondazione Policlinico Universitario A Gemelli-Rome, Rome
St Bartholomew's Hospital, London
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY